openPR Logo
Press release

Interview Released with Serbian Generics Drug Company Ahead of 23rd Pharmaceutical Pricing and Market Access Industry Summit

07-05-2017 04:48 PM CET | Health & Medicine

Press release from: SMi Group

Interview with Hemofarm

Interview with Hemofarm

SMi Group are delighted to have Serbian generics drug company, Hemofarm, present at the 23rd annual conference on Pharmaceutical Pricing and Market Access when it returns to Central London this October.

Highlights from the talk presented by Sasa Perovic, Head of the Pharmacoeconomics and Pricing, will include insight into Southeast Europe with a special focus on the impact of deteriorating local currencies.

Sasa Perovic is an expert in building pharmacoeconomic models in emerging markets within the Western Balkan region. In his current work, he is involved in preparing for product launches through reimbursement processes and market access strategy. In the run up to his address, SMi Group caught up with him to discuss the upcoming conference and current industry challenges.

From the answers provided, it is apparent that Real World Data continues to play a large role in pharmaceutical pricing and market access.

“Nowadays, Real World Data means the accumulation of as much detail as possible about a subject group, a population and the use of this information, to measure how a certain drug may be effective. At the end of earlier phase trials, the safety of the medicine can pass for market approval but this doesn’t mean it’s necessarily effective. With new technologies, we can now capture real world data to measure the effectiveness of a drug in a real subject in the right environment, continuously at the right time.”

The full interview is available to read in the event download center at http://www.smi-online.co.uk/goto/2017europricing.asp#tab_downloads

The 23rd annual Pharmaceutical Pricing and Market Access conference will take place on 11th & 12th Oct 2017 at the Holiday Inn Kensington Forum, London, UK.

Other notable speakers will include AstraZeneca, Shire, Sobi, Teva, Grifols, Allergan and Mylan. A full speaker line-up and detailed conference agenda is available at http://www.pharmaceuticalpricing.co.uk/openpr

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

2 Floor Harling House
47-51 Great Suffolk Street

Contact Information:
For media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk
For all other enquires contact the team on Tel: +44 (0)20 7827 6000 or email events@smi-online.co.uk

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Interview Released with Serbian Generics Drug Company Ahead of 23rd Pharmaceutical Pricing and Market Access Industry Summit here

News-ID: 610490 • Views:

More Releases from SMi Group

Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Conference
Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Con …
SMi Reports: Exclusive speaker interview with Todd Krueger at AOBiome released for the Pain Therapeutics Conference The pain therapeutics industry has grown at an exponential rate in recent years. The 22nd Annual Pain Therapeutics conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation. Industry leaders will uncover the
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual Highly Potent Active Pharmaceutical Ingredients Conference.
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual High …
Now in its 6th year, the Highly Potent Active Pharmaceutical Ingredients conference offers you peer-to-peer networking with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more. Taking place on 9th and 10th May in London, UK. With a key focus on expanding your community and exploring the latest developments in the industry at this two-day event, including key regulatory updates, and leading case studies from leading
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference in Boston, USA
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast C …
SMi Group Reports: Keynote FDA speaker Dr. John Arigo, to present at the 4th Annual Pharmaceutical Microbiology East Coast, taking place in just 3 weeks' time on April 27th and 28th, 2022. With just three weeks remaining until the highly anticipated conference, SMi Group are delighted to announce a key FDA Speaker joining the 5th Annual Pharmaceutical Microbiology East Coast Conference. This event will take place on April 27th and
Group Captain (ret'd) Robert Daisley invites you to attend Air Mission Planning …
SMi Group reports: Chairman Group Captain (ret'd) Robert Daisley of the Air Mission Planning and Support Conference cordially invites experts to join the conference in London, UK in one week. With only one week remaining, SMi Group is delighted to publish an invitation letter for SMi's 13th Annual Air Mission Planning & Support Conference, taking place on the 6th and 7th April 2022 in London, UK from the conference chairman. The

All 5 Releases


More Releases for Hemofarm

Lorazepam Tablets Market Insights by Growth, Emerging Trends and Forecast By 203 …
In recent years, the Global Lorazepam Tablets Market has witnessed significant growth and is expected to continue to do so during the forecast period 2023-2030. This report aims to provide a comprehensive analysis of the market's critical aspects, including its strengths, weaknesses, opportunities, and threats. With the help of SWOT and Porter's Five Forces analysis, we will explore the different players operating in the market and the microeconomic and macroeconomic
Ramipril (CAS 87333-19-5) Market 2023-2030: High-growth Segments and their Share …
In recent years, the Global Ramipril (CAS 87333-19-5) Market has witnessed significant growth and is expected to continue to do so during the forecast period 2023-2030. This report aims to provide a comprehensive analysis of the market's critical aspects, including its strengths, weaknesses, opportunities, and threats. With the help of SWOT and Porter's Five Forces analysis, we will explore the different players operating in the market and the microeconomic and
Lorazepam Tablets Market Trend and Set for Robust Growth During 2021-2027 & Covi …
A new detailed report named as Global Lorazepam Tablets market is released now for the benefit of the market players. This report is highly based on the elaborate market study. Information on the recent market trends, current market scenario and market growth is an important instrument to grow and survive in the ever-evolving competitive industry. It helps the new layers to develop a constant strategy which is flexible to
What Are the Chances of Ramipril (CAS 87333-19-5) Industry to Grow in Near Futur …
A New Market study by Research N Reports on the Global Ramipril (CAS 87333-19-5) Market has been released with reliable information and accurate forecasts for a better understanding of the current and future market scenarios. The report offers an in-depth analysis of the global market, including qualitative and quantitative insights, historical data, and estimated projections about the market size and share in the forecast period. The forecasts mentioned in the
Global Idarubicin (CAS 58957-92-9) Market Insights, Industry Scope and Forecast …
A New Market study by Research N Reports on the Global Ramipril (CAS 87333-19-5) Market has been released with reliable information and accurate forecasts for a better understanding of the current and future market scenarios. The report offers an in-depth analysis of the global market, including qualitative and quantitative insights, historical data, and estimated projections about the market size and share in the forecast period. The forecasts mentioned in the
Global and China Ramipril (CAS 87333-19-5) Industry, 2017 Market Research Report
This report studies the Ramipril (CAS 87333-19-5) market status and outlook of global and major regions, from angles of manufacturers, regions, product types and end industries; this report analyzes the top manufacturers in global and major regions, and splits the Ramipril (CAS 87333-19-5) market by product type and applications/end industries. The global Ramipril (CAS 87333-19-5) market is valued at XX million USD in 2016 and is expected to reach XX million